Braizon Therapeutics, Inc., a biomed company, engages in research and development of new drugs, diagnostics, and life science research reagents for the central nervous system (lat. systematis nervosi centralis). Based on the outcomes of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, the company applied an innovative technology that provides drug delivery across the blood-brain barrier (BBB) in close combination with nano-material engineering and neuroscience expertise, respectively. In addition, Braizon Therapeutics was founded in 2015 and is based in Tokyo, Japan.
The blood-brain barrier (BBB) is a cellular roadblock between circulating blood and brain tissue, which selectively allows only the passage of nutrients essential for brain activity to cross the cerebrovascular endothelial cells. By restricting the passage of chemicals into the central nervous system, the BBB limits the delivery of therapeutic drugs to the brain, adding extreme difficulty to the development of medicines for brain diseases. Therefore, technology for drug delivery to the brain is attracting attention as a breakthrough technology for pharmaceutical companies worldwide that focus on central nervous system diseases.
Therefore, Braizon's technology utilizes a unique mechanism that causes the brain to selectively take up drugs encapsulated within glucose labelled nanoparticles (nanomachines) with high efficiency, across the BBB, and into the brain via control of blood glucose levels. As these nanomachines can encapsulate a variety of therapeutic compounds (including nucleic acid medicines, antibodies, and low-molecular-weight compounds), Braizon’s technology may deliver medicines to the brain that previously would not have been considered possible.
In addition, Braizon Therapeutics, Inc. has secured 645 million yen through a third-party allotment of shares to three venture capital companies, including two new investors. The company's innovative nanotechnologies break through the blood-brain barrier, which is currently the greatest impediment to treating central nervous system diseases such as Alzheimer's disease (lat. morbus Alzheimerianus), and can deliver drugs to the brain with unprecedented efficiency.
The raised funds will enable Braizon to promote it’s R&D in earnest, set up an R&D center in the United States as a part of Braizon’s business expansion, and promote joint development with domestic and overseas pharmaceutical collaborators in both the public and private sectors.